high-risk myelodysplastic syndrome
Roche announces phase 3 results for KRAS G12C-mutated non-small cell lung cancer
The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care
Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo
NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment
Roche’s fenebrutinib receives FDA filing acceptance for relapsing and primary progressive MS
If approved, this treatment would offer a new option for the nearly one million Americans living with MS
Novartis’ Cosentyx gets positive CHMP opinion for polymyalgia rheumatica
If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica
Roche and Dualitas Therapeutics announce research collaboration worth up to $1bn
The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases
Roche’s Enspryng gets FDA Priority Review for autoimmune disease with no approved treatments
MOGAD, a rare disease of the central nervous system, can attack optic nerves, the spinal cord and the brain
Novartis announces trial results for remibrutinib in relapsing multiple sclerosis
MS affects nearly three million people worldwide and has three main types
Pfizer and Valneva’s application for Lyme disease vaccine candidate validated by EMA
There are currently no approved human vaccines for Lyme disease
Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer
More than 186,000 men are diagnosed each year with mHSPC globally
Pfizer announces phase 3 results for nonsegmental vitiligo treatment
Litfulo delivered significant, clinically meaningful improvements for both face and body
Pfizer’s Talzenna plus Xtandi gets FDA Priority Review for metastatic prostate cancer
The phase 3 trial showed greater than 50% improvement in radiographic progression-free survival
Novartis to acquire Myricx Bio in deal worth $1.5bn
Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates